3 completed, 1 terminated. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Terminated 1 |
Follow Quantum Genomics SA: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction Ramipril, Firibastat - Myocardial Infarction | Phase 2 | Completed | Quantum Genomics SA | 295 | 2019-06-04 | 2023-02-27 |
| Novel Evaluation With QGC001 in Hypertensive Overweight Patients of Multiple Ethnic Origins QGC001 - Hypertension | Phase 2 | Completed | Quantum Genomics SA | 256 | 2017-10-13 | 2018-12-11 |
| QUantum Genomics Incremental Dosing in Heart Failure - QUID-HF QGC001, Placebo - Heart Failure | Phase 2 | Terminated | Quantum Genomics SA | 23 | 2016-06-01 | 2018-10-16 |
| Phase IIa Study of the Product QGC001 Compared With Placebo in Patients With Essential Hypertension QGC001, Placebo - Essential Hypertension | Phase 2 | Completed | Quantum Genomics SA | 34 | 2015-01-01 | 2016-09-28 |
Essential Hypertension (1) · Heart Failure (1) · Hypertension (1) · Myocardial Infarction (1)
Ramipril (1) · firibastat (1)
France (3) · Germany (2) · Hungary (2) · Poland (2) · United Kingdom (2) · Czechia (1) · Netherlands (1) · Norway (1) · Slovakia (1) · Spain (1) · United States (1)
Faiez Zannad, MD (1) · Gilles Montalescot, MD, PhD (1) · Keith C. Ferdinand, MD FACC (1)
PMID 33027067, PMID 30882604, PMID 31014072, PMID 31923435, PMID 36757536